The story of NeonMind Biosciences Inc. (OTCQB: NMDBF) (CSE: NEON) (FROM: 6UF) has filed a new patent application with the U.S. Patent and Trademark Office in connection with a new weight loss mechanism targeting specific fat subtypes.
The provisional patent application contains data derived from the recent preclinical animal study by NeonMind, which integrates new findings that show, in addition to the repetition of the weight-modulating effect of psilocybin, seen in previous studies that the Targeted reduction of specific fat subtypes may have a positive effect on metabolic and cardiovascular health.
The area strengthens NeonMind’s growing IP portfolio and differentiates the commercial profiles of its drug candidates. The company plans to release further details on the results of the study.
If granted, the NeonMind patent can support pharmaceutical assets until at least 2042. NeonMind’s leading candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybina connection with psychotherapyreach sustainable weight loss for patients suffering from obesity. NeonMind’s additional drug candidate, NEO-002, employs low dose psilocybin to control appetite.
“We are impressed by the unique findings of our preclinical studies, which have demonstrated sustainable therapeutic benefits for weight management in the animal model. Importantly, our new findings provide an opportunity to develop our drugs with highly differentiated target product profiles and broad commercial capabilities,” he said. Robert TessaroloPresident & CEO of NeonMind.
“With the advancement of our research programs and further expansion of our IP portfolio, NeonMind is positioning itself as a leading innovator in the development of new psychedelic treatments focused on serving the weight management and obesity market, which has historically been underserved and where a new, effective approach is desperately needed to help people live fuller and healthier lives, ”Tessarolo concluded.
To hear more about the important and fascinating scientific advances and to meet face-to-face with some of the professionals and market leaders of this nascent industry, join us at the Benzinga Psychedelics Capital Conference on April 19, 2022 at the Fontainebleau Miami Beach where we will bring leaders of the greatest. publicly traded psychedelics companies with investors from all over North America.
Tickets for this first meeting are still available.
Photo: Powered by Marco Allegretti on Unsplash
Add Comment